Biomedical Sciences
Raquel S. Salinas González, N/A, MD (she/her/hers)
PM&R Physician
Hospital Clínic de Barcelona
Barcelona, Catalonia, Spain
Daniela Salinas-Camacho, MLS
Medical Laboratory Scientist
Hematology Department. Massachusetts General Hospital, Boston, MA.
Boston, Massachusetts, United States
Blanca De Moner, PhD student
Biomedical Researcher
Fundació i Institut de Reserca Josep Carreras Contra la Leucèmi
Barcelona, Catalonia, Spain
Julia Martinez-Sanchez, BD
Biomedical Sciences
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain
Barcelona, Catalonia, Spain
Laia Guardia, BSN
Nurse (IPA)
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain.
Barcelona, Catalonia, Spain
María Suárez-Lledó, MD
Hematologist
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain
Barcelona, Catalonia, Spain
Laura , Rosiñol, MD
Hematologist
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain
Barcelona, Catalonia, Spain
Francesc Fernández-Avilés, MD, PhD
Hematologist
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain
Barcelona, Catalonia, Spain
Concepción Closa, MD, PhD
PM&R Physician
Physical Medicine and Rehabilitation Department. Hospital Clínic de Barcelona, Barcelona, Spain
Barcelona, Catalonia, Spain
Raquel Sebio, PT, PhD
Physiotherapist
Physical Medicine and Rehabilitation Department. Hospital Clínic de Barcelona, Barcelona, Spain
Barcelona, Catalonia, Spain
Carmen Martínez, MD, PhD
Hematologist
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain
Barcelona, Catalonia, Spain
Montserrat Rovira, MD, PhD
Hematologist
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain
Barcelona, Catalonia, Spain
Maribel Díaz-Ricart, PhD
Senior Rresearcher
Hemostasis and Erythropathology Laboratory, Hematopathology, Department of Pathology, Biomedical Diagnostic Center, Hospital Clínic de Barcelona, Spain.
Barcelona, Catalonia, Spain
María Queralt Salas, MD, PhD
Hematologist
Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic de Barcelona, Barcelona, Spain
Barcelona, Catalonia, Spain
Frailty increases morbidity andmortalityin allo-HCT patients. Previous studies in older adults and individuals with cardiovascular risk have linked frailty to endothelial dysfunction, though this association remains unreported in allo-HCT. Given that endothelial activation occurs early post-allo-HCT due to conditioning, GVHD prophylaxis, alloreactivity, and complications, this study explores whether prehabilitation could modulate endothelial responses.
Design:
Between 2022-2025, all adult patients undergoing allo-HCT were categorized as fit, pre-frail or frail using the HCT Frailty Scale at admission (Salas et al., 2023). Since 2023, all patients underwent a structured exercise-based telematic prehabilitation.
Endothelial activation was assessed using the Endothelial Activation and Stress Index (EASIX), at admission and days 0, +7, +14, +21, +28, +100, and +180 post-transplant. Biomarkers of endothelial activation and inflammation (VWF antigen, VCAM-1, thrombomodulin, REG3α, sTNFRI, ST2) were longitudinally quantified in plasma and sera samples.
Results:
Baseline characteristics and transplant procedures were similar across groups, except for a higher number of comorbidities in frail patients(p=0.023).
EASIX trends showed a peak at day +21 in all frailty groups. Fit patients showed transient endothelial activation with progressive recovery. Pre-frail patients had sustained activation, while frail showed the highest and most prolonged elevations with limited recovery. Biomarkers followed a similar trend: frail patients had early VWF stabilization, late VCAM-1 increases, and progressive thrombomodulin elevation, suggesting persistent endothelial dysfunction.
Prehabilitated patients showed attenuated EASIX peaks and more favorable biomarker trajectories: lower early VCAM-1 and TNFR1 elevations, stable thrombomodulin levels, higher late VWF concentrations and contained ST2 and REG3α-levels, suggesting enhanced endothelial regulation.
Overall survival at 1-year was highest in pre-frail patients (87.3%), followed by fit (79.2%) and frail (62.5%; p=0.288).
Conclusion:
Frailty is associated with intensified and prolonged endothelial activation following allo-HCT, Telematic prehabilitation may mitigate these effects by enhancing endothelial and inflammatory regulation. These findings support incorporating prehabilitation and frailty assessment could reduce patient vulnerability.